Thomas Januario

Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib

David A. Eberhard, Bruce E. Johnson, Lukas C. Amler et al. · Journal of Clinical Oncology · 2005 · 1.5K citations · Full text

Medicine, Oncology, Pharmacology +17

A paracrine requirement for hedgehog signalling in cancer

Robert L. Yauch, Stephen E. Gould, Suzie J. Scales et al. · Nature · 2008 · 955 citations

Medicine, Cancer Biology, Oncology +14

<i>Smoothened</i> Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma

Robert L. Yauch, Gerrit J.P. Dijkgraaf, Bruno Alicke et al. · Science · 2009 · 844 citations · Full text

Medicine, Cancer Biology, Oncology +17

Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL

Klaus W. Wagner, Elizabeth A. Punnoose, Thomas Januario et al. · Nature Medicine · 2007 · 603 citations

Life Sciences, Cell Biology, Oncology +16

Epithelial versus Mesenchymal Phenotype Determines <i>In vitro</i> Sensitivity and Predicts Clinical Activity of Erlotinib in Lung Cancer Patients

Robert L. Yauch, Thomas Januario, David A. Eberhard et al. · Clinical Cancer Research · 2005 · 491 citations · Full text

Medicine, Oncology, Pharmacology +17